Federal Circuit says biosimilar applicants can decline patent dance

The Federal Circuit in Amgen v Sandoz was split two ways, holding biosimilar applicants can opt out of the patent dance provisions but must wait for approval before giving 180 days notice of marketing. Applicants and patent owners now face tricky strategic questions